Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

Recruiting now · Phase 1

Conditions studied: Gliomas Harboring IDH1 and/or IDH2 Mutations

In brief

This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations

Key facts

Study ID

NCT07025018

Run by

Hutchmed

People needed

52

Starts

2025-07-15

Expected to finish

2027-12-01

Last updated by the study team

2025-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Fully informed about the study and voluntarily sign the informed consent form (ICF).
• Age ≥ 18 years.
• Safety Lead-In Phase: Patients with gliomas of a documented IDH1 and/or IDH2 mutation. Perioperative Study Phase: Patients with gliomas of definitive or suspected IDH1 and/or IDH2 mutations scheduled for surgery.
• All patients must have at least one measurable lesion.
• Karnofsky Performance Status (KPS) score ≥ 80% .
• In the investigator's judgment, a life expectancy of ≥ 12 weeks.
• Sufficient bone marrow and organ function.

You may not qualify if…

• Previous treatment with IDH inhibitors.
• Unresolved toxicity from previous antitumor treatments not reverted to ≤ Grade 1 (except for alopecia, skin pigmentation changes, and ≤ Grade 2 peripheral neuropathy).
• Patients assessed by researchers to have high-risk or unstable conditions.
• Having other malignancies or a history of other malignancies within 5 years prior to screening.
• History of clinically significant liver disease, including active infection with viral hepatitis, or other active hepatitis, alcoholic liver disease, cirrhosis, etc.
• Patients with HIV infection.
• Pregnancy (positive pregnancy test before dosing) or currently breastfeeding women.
• Presence of diseases or conditions affecting drug absorption.
• Any other conditions, in the investigator's judgment, unsuitable for the study drug, will result in exclusion.

Where it is running

• Huashan Hospital affiliated to Fudan University — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.